Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
152.43
-2.15 (-1.39%)
Feb 21, 2025, 4:00 PM EST - Market closed
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Ascendis Pharma stock have an average target of 197.36, with a low estimate of 140 and a high estimate of 289. The average target predicts an increase of 29.48% from the current stock price of 152.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 7 | 7 |
Buy | 6 | 6 | 6 | 6 | 6 | 6 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 13 | 13 | 13 | 13 | 14 | 14 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Evercore ISI Group | Evercore ISI Group | Buy Maintains $220 → $260 | Buy | Maintains | $220 → $260 | +70.57% | Feb 18, 2025 |
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $200 → $225 | Strong Buy | Maintains | $200 → $225 | +47.61% | Feb 13, 2025 |
JP Morgan | JP Morgan | Buy Maintains $167 → $168 | Buy | Maintains | $167 → $168 | +10.21% | Feb 13, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +11.53% | Feb 11, 2025 |
JP Morgan | JP Morgan | Buy Maintains $165 → $167 | Buy | Maintains | $165 → $167 | +9.56% | Jan 29, 2025 |
Financial Forecast
Revenue This Year
536.39M
from 363.64M
Increased by 47.51%
Revenue Next Year
1.01B
from 536.39M
Increased by 88.30%
EPS This Year
-3.95
from -6.53
EPS Next Year
1.18
from -3.95
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 786.5M | 1.6B | 2.7B | ||
Avg | 536.4M | 1.0B | 1.6B | ||
Low | 430.2M | 703.8M | 1.2B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 116.3% | 205.7% | 166.0% | ||
Avg | 47.5% | 88.3% | 56.7% | ||
Low | 18.3% | 31.2% | 15.1% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.49 | 7.03 | 11.26 | ||
Avg | -3.95 | 1.18 | 6.75 | ||
Low | -6.73 | -3.05 | 3.33 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 854.8% | ||
Avg | - | - | 472.8% | ||
Low | - | - | 182.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.